Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR: Customize Ibrutinib Treatment Regimens in Untreated CLL
NCT05963074Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Best Overall Response Rate at 5 years. Started May 2024; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05963074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963074.